Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Literature DB >> 24493721

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Karen H Lu¹, Marie E Wood, Molly Daniels, Cathy Burke, James Ford, Noah D Kauff, Wendy Kohlmann, Noralane M Lindor, Therese M Mulvey, Linda Robinson, Wendy S Rubinstein, Elena M Stoffel, Carrie Snyder, Sapna Syngal, Janette K Merrill, Dana Swartzberg Wollins, Kevin S Hughes.

Abstract

Entities: Disease

Mesh：

Year: 2014 PMID： 24493721 PMCID： PMC3940540 DOI： 10.1200/JCO.2013.50.9257

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

48 in total

Review 1. AGA technical review on hereditary colorectal cancer and genetic testing.

Authors: F M Giardiello; J D Brensinger; G M Petersen
Journal: Gastroenterology Date: 2001-07 Impact factor: 22.682

2. Accuracy of cancer family histories: comparison of two breast cancer syndromes.

Authors: Katherine A Schneider; Lisa M DiGianni; Andrea Farkas Patenaude; Neil Klar; Jill E Stopfer; Kathleen A Calzone; Frederick P Li; Barbara L Weber; Judy E Garber
Journal: Genet Test Date: 2004

3. Accuracy of family history of cancer: clinical genetic implications.

Authors: R H Sijmons; A E Boonstra; J Reefhuis; J M Hordijk-Hos; H E de Walle; J C Oosterwijk; M C Cornel
Journal: Eur J Hum Genet Date: 2000-03 Impact factor: 4.246

Review 4. Inherited susceptibility for pediatric cancer.

Authors: Sharon E Plon; Katherine Nathanson
Journal: Cancer J Date: 2005 Jul-Aug Impact factor: 3.360

5. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Authors: Donald A Berry; Edwin S Iversen; Daniel F Gudbjartsson; Elaine H Hiller; Judy E Garber; Beth N Peshkin; Caryn Lerman; Patrice Watson; Henry T Lynch; Susan G Hilsenbeck; Wendy S Rubinstein; Kevin S Hughes; Giovanni Parmigiani
Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544

6. Prediction of germline mutations and cancer risk in the Lynch syndrome.

Authors: Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani
Journal: JAMA Date: 2006-09-27 Impact factor: 56.272

Review 7. Hereditary breast cancer in Jews.

Authors: Wendy S Rubinstein
Journal: Fam Cancer Date: 2004 Impact factor: 2.375

8. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

Authors: Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog
Journal: Gynecol Oncol Date: 2007-11 Impact factor: 5.482

9. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors: J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal: Nat Genet Date: 1995-10 Impact factor: 38.330

10. PancPRO: risk assessment for individuals with a family history of pancreatic cancer.

Authors: Wenyi Wang; Sining Chen; Kieran A Brune; Ralph H Hruban; Giovanni Parmigiani; Alison P Klein
Journal: J Clin Oncol Date: 2007-04-10 Impact factor: 44.544

68 in total

1. Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.

Authors: Kathryn J Ruddy; Betsy C Risendal; Judy E Garber; Ann H Partridge
Journal: J Clin Oncol Date: 2015-12-28 Impact factor: 44.544

2. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Authors: Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu
Journal: Gynecol Oncol Date: 2017-06-10 Impact factor: 5.482

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Review 1. AGA technical review on hereditary colorectal cancer and genetic testing.

2. Accuracy of cancer family histories: comparison of two breast cancer syndromes.

3. Accuracy of family history of cancer: clinical genetic implications.

Review 4. Inherited susceptibility for pediatric cancer.

5. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

6. Prediction of germline mutations and cancer risk in the Lynch syndrome.

Review 7. Hereditary breast cancer in Jews.

8. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

9. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

10. PancPRO: risk assessment for individuals with a family history of pancreatic cancer.

1. Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.

2. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

3. A model for patient-direct screening and referral for familial cancer risk.

Review 4. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Review 5. Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.

6. Placing negative multi-gene panel results into clinical context.

Review 7. What characterizes cancer family history collection tools? A critical literature review.

Review 8. Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review.

9. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.

10. Compatibility of Family History Cancer Guidelines With Meaningful Use Standards.